Prognosis of Behavioral Addiction in Parkinson's Disease

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02671240

Acronym

PROBA-PD

Enrollment

164

Registered

2016-02-02

Start date

2016-10-24

Completion date

2019-04-19

Last updated

2023-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Addiction

Keywords

Parkinson disease, behavioral addiction, akinéto-rigid syndrome, dopamine agonist

Brief summary

Our hypothesis is that the conventional treatment of Behavioral Addiction in Parkinson's disease is often not effective, and that affects the motor aspects (worsening akinéto-rigid syndrome and / or worsening of dyskinesia due to higher levodopa doses to compensate for the drop in behavioral addictions) and non-motor (withdrawal syndrome dopamine agonist) anxiously including apathy. Our goal is to describe the natural history of Behavioral Addiction under the effect of the evolution of the disease and adapt treatment according to the prior art, through a study of a larger population of patients than in the few published studies.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age greater than or equal to 30 years * Parkinson's disease according to the criteria of UKPDSBB * Time evolution of the top disease or equal to 5 years

Exclusion criteria

* Lack of Parkinson's disease and atypical parkinsonism * Patient not previously included in PD-BADGE

Design outcomes

Primary

Measure	Time frame
Survival time before disappearance of behavioral addiction defined by a score of less than 2 on the scale of behavioral assessment of Parkinson's disease	12 months after selection

Countries

France

Outcome results